TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03258593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicineum
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
Study: NCT00011193

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
Study: NCT01893840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx
Description: Boot-shaped pressure chamber generating pulsating negative pressure
Study: NCT03258593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicineum
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
Study: NCT03187951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Questionnaire and Nutritional Counseling
Description: Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Participants receive a booklet that contains a stretching guide with full-body stretches and safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Strength Training Exercises
Description: Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
Study: NCT03187951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
Study: NCT03258593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicineum
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Study: NCT01429246

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Salt
Description: Estimated Household Individual Consumption of 30 grams per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Substitute
Description: Estimated 30 grams per day per household member
Study: NCT03971695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: Capsule or Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule or Oral solution
Study: NCT03905811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin 5 MG
Description: 5 milligrams by mouth daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule by mouth daily at bedtime
Study: NCT02213679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid
Description: Dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04485780

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin type A
Description: In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
Study: NCT01140607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT01962064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Study: NCT00795132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
Study: NCT02907125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEHER Intervention delivered by TSM
Description: SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEHER Intervention delivered by SM
Description: The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tarang AEP
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tarang AEP
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tarang AEP
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
Study: NCT00822887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Description: All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
Study: NCT01256996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air abrasion of the implant surface with a low abrasive powder
Description: Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
Study: NCT02586324

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: global medium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSM
Study: NCT02924649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Intensive mobilisation
Description: The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
Study: NCT02835157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution
Description: Multiple electrolyte solution as boluses would be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%sodium chloride
Description: saline as boluses would be administered
Study: NCT00672217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Description: Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Placebo Treatment
Description: Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
Study: NCT03911674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral manual stimulation of feeding in preterm infants
Description: Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
Study: NCT02360007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Buprenorphine Treatment (IBT)
Description: The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad
Study: NCT00046839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT03258593

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography (CT) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography (CT) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography (CT) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography (CT) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
Study: NCT02146989

Intervention type: OTHER
Intervention: reproducibility of upper extremity strength measurements
Description: inter-rater reliability and test-retest reliability

Intervention type: OTHER
Intervention: reproducibility of upper extremity strength measurements
Description: inter-rater reliability and test-retest reliability
Study: NCT01232972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrification of oocytes
Description: eggs will be preserved via vitrification the day they are retrieved from the participant
Study: NCT03258593

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) at screening and every 12 months while on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
Study: NCT01929044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 654-II (anisodamine)
Description: 10mg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan® (hyoscine butylbromide)
Description: 20mg injection
Study: NCT00795132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion.
Study: NCT01752569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib.
Study: NCT01741194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: AC-1204 taken once daily, by mouth
Study: NCT00046839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT01741194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily, by mouth
Study: NCT00046839

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01664169

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT00795132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.